Monday, January 18, 2021

Group led by EX-AIIMS director slams people for doubting Covid vaccine

- Advertisement -

1 mn Covid-19 vaccinations in New York by end of Jan attainable but challengingNew Delhi, Jan 14 (IANS) A group of 49 doctors, scientists and medical professionals, led by former AIIMS director Tirath Das Dogra, have come forward in support of the homemade Covid-19 vaccines and slammed those casting aspersions on their efficacy.

“We condemn the irresponsible statements made by people with vested interests in print, electronic and social media defaming the Indian scientific community and casting aspersions upon its integrity by making politicised statements doubting the recent research in the field of Covid-19 vaccines,” said the statement issued by Dogra.

“Though the efficacy data is not available, the safety parameters of Covaxin are very good and there is a robust immune response seen with this vaccine. Further, this vaccine is a whole virus inactivated vaccine which may have better protection even against mutant strains of the virus as the immune response will be against multiple antigens and not only against Spike protein,” it added.

READ ALSO:  Centre: India''s corona cases 1/84 compared to 20 countries

Dogra said that such reprehensible utterances are causing huge credibility crisis for the Indian scientific community which has devoted its lifetime to make India a name to reckon with in the export of vaccines all over the world.

Many political leaders, including those from the Congress, have said that the government should not have allowed the use of Covaxin without conducting Pahse 3 trials.

But the former AIIMS director said that there is a vision to make India a global leader in the field of scientific research.

“Due to our untiring efforts, India has emerged a global leader in supply of vaccines to the world. Vaccines are exported from India to over 188 countries. Currently, more than two thirds of the total volume of the vaccines manufactured is exported while the rest is utilised domestically. The Indian vaccine market reached a value of Rs 94 billion in 2019, and has still got unused potential for the future,” the statement said.

READ ALSO:  Indoor workouts up 40% in India as people stay home: Garmin
READ ALSO:  China sets up military base at Finger 5 of Pangong Lake, cutting off Indian Army

It further said that the DGCI has granted the approval after a subject expert committee of the Central Drugs Standard Control Organisation (CDSCO) recommended the two vaccines (Covishield and Covaxin) for emergency use in India. Covishield was recommended for emergency use on January 1, whereas Covaxin was recommended for restricted use on January 2.

Though Covishield still needs data from India on immunogenicity and efficacy, it has been given emergency use authorisation keeping in mind the difficult times caused by the Covid-19 pandemic.

Source: IANS

India Updates
India Updates is an independent news & Information website. Follow us for regular updates on News and Information.

Follow Us On

Related News


Please enter your comment!
Please enter your name here

Trending Topics In India

Covid 19 India Updates

Trending News In India

Trending Showbiz

Trending Sports

Latest Trending News In India

Exports of SII vaccine blocked till March-April

New Delhi, Jan 18 (IANS) Exports of the Oxford-AstraZeneca vaccine by the Serum Institute of India are currently blocked until March or April, as...

Farmers’ R-Day parade to showcase ‘agricultural reality’

New Delhi, Jan 18 (IANS) Tens of thousands of farmers protesting new agricultural laws along the Delhi borders seeking withdrawal of the contentious legislations,...

Parliamentary panel summons FB, Twitter officials on Jan 21

New Delhi, Jan 17 (IANS) The Parliamentary Committee on Information Technology has issued summons to officials of Facebook and Twitter for January 21, to...

447 adverse events across India post-vaccination, 3 serious

New Delhi, Jan 17 (IANS) A total of 447 Adverse Events Following Immunisation (AEFI) have been reported in the last two days of the...